Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases

Zhujiang Hospital

Status: Unknown

Conditions: Atherosclerotic Cardiovascular Disease; Inflammatory Bowel Disease; Type2 Diabetes Mellitus; Colorectal Cancer

Treatments: Other: Observational studies, no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04924686

ZhujiangH-1

Details and patient eligibility

About

Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).

Full description

Previous studies have shown that NOD2 gene mutants were associated with the Crohn's disease (CD), colorectal cancer (CRC) and many other diseases, suggesting the critical role of NOD2 signaling in human physiology and pathogenethesis. However, whether decreased NOD2 ligands also contributed to these diseases is unknown. In this study, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ). For each of the patient, a sex- and age- matched control were chosen. Both the targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters were used to test NOD2 ligands in the fecal and plasma samples.

Enrollment: 600 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Males or females at least 18-70 years old.
2. Patient able to give informed consent.
3. Patient with biopsy-proven CRC
4. Patient with biopsy-proven Crohn's disease (CD) or ulcerative colitis(UC), in the active phase.
5. patients with clinical diagnosed DM2
6. patients with ACVD:coronary angiography more than 50% stenosis in single or multiple vessels.
7. The age- and sex- matched health controls for each patient.

Exclusion criteria

1.Use antibiotics or probiotics within the last 2 weeks.

Trial design

600 participants in 5 patient groups

Crohn's disease

Description:

The fecal and plasma were collected

Treatment:

Other: Observational studies, no intervention

Ulcerative colitis

Description:

The fecal and plasma were collected

Treatment:

Other: Observational studies, no intervention

Diabetes mellitus, type 2

Description:

The fecal and plasma were collected

Treatment:

Other: Observational studies, no intervention

Atherosclerotic cardiovascular disease

Description:

The fecal and plasma were collected

Treatment:

Other: Observational studies, no intervention

Colorectal cancer

Description:

The fecal and plasma were collected

Treatment:

Other: Observational studies, no intervention